Hemispherx Biopharma Inc. v. Asensio

55 Pa. D. & C.4th 502, 2001 Pa. Dist. & Cnty. Dec. LEXIS 222
CourtPennsylvania Court of Common Pleas, Philadelphia County
DecidedSeptember 6, 2001
Docketno. 3970
StatusPublished

This text of 55 Pa. D. & C.4th 502 (Hemispherx Biopharma Inc. v. Asensio) is published on Counsel Stack Legal Research, covering Pennsylvania Court of Common Pleas, Philadelphia County primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hemispherx Biopharma Inc. v. Asensio, 55 Pa. D. & C.4th 502, 2001 Pa. Dist. & Cnty. Dec. LEXIS 222 (Pa. Super. Ct. 2001).

Opinion

SHEPPARD JR., J.,

Presently before this court is defendants’ motion for summary judgment, seeking to dismiss the action in its entirety. Defendants make several arguments in support of their motion. Certain arguments involve strict issues of law, while others involve issues of fact. This opinion is limited to a discussion of the issues of law, because it is evident to the court that genuine issues of material fact exist which preclude granting summary judgment. Further, resolution of the legal issues also demonstrates that summary judgment is not appropriate.

BACKGROUND1

This action arises from defendants’ alleged scheme to illegally manipulate the price of, and short-sell, plaintiff’s [505]*505common stock through defendants’ publication of allegedly defamatory statements in a series of research reports and/or press releases regarding plaintiff and plaintiff’s development of a certain anti-viral drug.

Plaintiff, Hemispherx Biopharma Inc. is a Delaware corporation with its principal place of business in Philadelphia, Pennsylvania. HBI is engaged in the business of researching, developing and testing experimental pharmaceutical compounds and drug technologies for regulatory approval and sale. Its primary focus has been the development and clinical testing of the anti-viral compound known as Ampligen for the possible treatment of viral afflictions such as chronic fatigue syndrome and chronic hepatitis. HBI’s common stock is currently traded on the American Stock Exchange.

Defendant, Asensio & Company Inc. is a Delaware corporation with its principal place of business in New York, New York. It is a registered broker and investment banking firm that publishes and distributes to the investing public analytical research reports regarding publicly-traded companies and trades securities of those companies for its own account. Defendant, Asensio.Com Inc. purportedly owns 100 percent of the shares of ACI, maintains ACI’s accounts and provides the necessary capital for ACI to conduct its business, including proprietary trading and the short-selling alleged in this action. Manuel P. Asensio, a citizen of New York, is the founder and chairman of ACI.

[506]*506In August 1998, defendants purportedly began to accumulate short positions in HBI in order to realize a profit which would occur from the erosion in the price of HBI’s common stock after the publication of the allegedly defamatory statements. On September 22, 1998, defendants produced and published, through means of interstate commerce including the Internet, a “research report” and accompanying press release, containing numerous statements about HBI and Ampligen. See pi. exhibit 33.2 This research report was accompanied by a “strong sell recommendation” with respect to HBI’s shares of common stock. Id. It was preceded by defendants’ statements which appeared in an article in the September 28, 1998 issue of Business Week which had been distributed on the Internet on September 17, 1998. See pi. exhibit 32. The report and accompanying press release included the following initial statements:

• Ampligen is “toxic;”

• Ampligen has “no medical or economic value;”

• Ampligen “is medically useless and an obsolete drug;”

• Ampligen is “off patent;”

• HBI has made “fraudulent misrepresentations about Ampligen’s FDA filing status and CFS earnings claims;”

[507]*507• HBI’s phase II clinical trial of Ampligen for use as a possible treatment for CFS was “neither placebo-controlled nor double blind” and “failed;”

• There is “no legitimate medical or business purpose for [HBI’s] continuing attempts to test Ampligen for treatment of CFS and other diseases;”

• HBI “is not and has never been engaged in any long-term project to create a new drug;”

• HBI has “purposefully cultivated” false claims regarding Ampligen “in order to defraud investors;”

• HBI “is promoting futile projects simply in order to enable insiders to sell their otherwise worthless stock to the public.” See pi. exhibit 33.

Defendants also published additional statements on ACI’s website and to third parties such as the FDA, the American Stock Exchange, the Securities Exchange Commission and Business Week magazine which are allegedly defamatory. Some of defendants’ statements also appeared in the September 23, 1998 issue of the Philadelphia Inquirer. See pi. exhibit 34. The publication of these statements allegedly caused the price of HBI’s common stock to decline precipitously, reduce the value of the company, and impaired HBI’s business relations with third parties.

This action originated in the federal court system over two years ago. It was transferred to this court on July 31, 2000, pursuant to 42 Pa.C.S. §5103. Plaintiff asserts four counts against defendants: (1) defamation; (2) disparagement; (3) intentional interference with existing and prospective business relations; and (4) civil conspiracy. Defendants move for summary judgment, asserting, in[508]*508ter alia, that (1) the challenged statements are not actionable since they are mere opinions based on disclosed facts; (2) the statements are substantially tme; (3) HBI is a public figure and cannot prove that the statements were made with actual malice; (4) HBI’s damages are not recoverable for a loss in market capitalization; (5) HBI cannot show a causal connection between the statements and the losses it allegedly suffered; (6) HBI cannot make out a claim for tortious interference based on difficulty to work with third parties on account of defendants’ statements; and (7) HBI fails to meet the plurality requirement to make out a claim for civil conspiracy where HBI does not identify the “John Doe” defendants which it alleges conspired with the named defendants to defame HBI.

For the reasons set forth, this court finds that defendants are not entitled to summary judgment as a matter of law.

DISCUSSION

Rule 1035.2 of the Pennsylvania Rules of Civil Procedure provides that a moving party is entitled to summary judgment if (1) there is no genuine issue of any material fact as to a necessary element of the cause of action or defense that could be established by additional discovery or expert report, or (2) after the completion of discovery, a party bearing the burden of proof on an issue has failed to produce evidence of facts essential to the cause of action or defense such that a jury could return a verdict in his favor. The moving party has the burden to prove that there is no genuine issue of material fact. Hagans v. Constitution State Service Co., 455 Pa. [509]*509Super. 231, 254, 687 A.2d 1145, 1156 (1997). Once the moving party meets this burden, the non-moving party must set forth specific facts showing that there is a genuine issue for trial. Id. The trial court’s function is to determine whether there are controverted issues of fact, not whether there is sufficient evidence to prove the particular facts. Id. at 254, 687 A.2d at 1157. A motion for summary judgment must be viewed in the light most favorable to the non-moving party, and all doubts as to the existence of a genuine issue of material fact must be resolved against the moving party. Pennsylvania State University v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

New York Times Co. v. Sullivan
376 U.S. 254 (Supreme Court, 1964)
Gertz v. Robert Welch, Inc.
418 U.S. 323 (Supreme Court, 1974)
Hutchinson v. Proxmire
443 U.S. 111 (Supreme Court, 1979)
Wolston v. Reader's Digest Assn., Inc.
443 U.S. 157 (Supreme Court, 1979)
Eric Waldbaum v. Fairchild Publications, Inc
627 F.2d 1287 (D.C. Circuit, 1980)
Iafrate v. Hadesty
621 A.2d 1005 (Superior Court of Pennsylvania, 1993)
Brown v. Philadelphia Tribune Co.
668 A.2d 159 (Superior Court of Pennsylvania, 1995)
Rutt v. Bethlehems' Globe Publishing Co.
484 A.2d 72 (Supreme Court of Pennsylvania, 1984)
Wilson v. Slatalla
970 F. Supp. 405 (E.D. Pennsylvania, 1997)
Skipworth v. Lead Industries Ass'n, Inc.
690 A.2d 169 (Supreme Court of Pennsylvania, 1997)
Pennsylvania State University v. County of Centre
615 A.2d 303 (Supreme Court of Pennsylvania, 1992)
Crawford v. Manhattan L. Ins. Co. of NY
221 A.2d 877 (Superior Court of Pennsylvania, 1966)
Griffith v. United Air Lines, Inc.
203 A.2d 796 (Supreme Court of Pennsylvania, 1964)
Gross v. New York Times Co.
623 N.E.2d 1163 (New York Court of Appeals, 1993)
Constantino v. University of Pittsburgh
766 A.2d 1265 (Superior Court of Pennsylvania, 2001)
Pro Golf Manufacturing, Inc. v. Tribune Review Newspaper Co.
761 A.2d 553 (Superior Court of Pennsylvania, 2000)
DiSalle v. P.G. Publishing Co.
544 A.2d 1345 (Superior Court of Pennsylvania, 1988)
Hagans v. Constitution State Service Co.
687 A.2d 1145 (Superior Court of Pennsylvania, 1997)
Ratti v. Wheeling Pittsburgh Steel Corp.
758 A.2d 695 (Superior Court of Pennsylvania, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
55 Pa. D. & C.4th 502, 2001 Pa. Dist. & Cnty. Dec. LEXIS 222, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hemispherx-biopharma-inc-v-asensio-pactcomplphilad-2001.